| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Revance Therapeutics, Inc. | Director | Common Stock | 0 | $0 | $3.65 | Feb 6, 2025 | Direct |
| Revance Therapeutics, Inc. | Director | Stock Option (Right to buy) | 23.5K | May 1, 2024 | Direct | ||
| Contineum Therapeutics, Inc. | Director | Stock Option (right to buy) | 14.8K | Jun 26, 2025 | Direct | ||
| Arcellx, Inc. | Director | Stock Option (right to buy) | 9.17K | May 29, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| CTNM | Contineum Therapeutics, Inc. | Jun 26, 2025 | 1 | $0 | 4 | Jun 26, 2025 | Director |
| ACLX | Arcellx, Inc. | May 29, 2025 | 1 | $0 | 4 | May 30, 2025 | Director |
| RVNC | Revance Therapeutics, Inc. | Feb 4, 2025 | 2 | -$60.9K | 4 | Feb 6, 2025 | Director |
| ACLX | Arcellx, Inc. | May 28, 2024 | 1 | $0 | 4 | Jun 6, 2024 | Director |
| CTNM | Contineum Therapeutics, Inc. | May 24, 2024 | 1 | $0 | 4 | May 29, 2024 | Director |
| RVNC | Revance Therapeutics, Inc. | May 1, 2024 | 2 | $0 | 4 | May 3, 2024 | Director |
| ACLX | Arcellx, Inc. | Apr 16, 2024 | 4 | -$451K | 4 | Apr 18, 2024 | Director |
| CTNM | Contineum Therapeutics, Inc. | Apr 4, 2024 | 0 | $0 | 3 | Apr 4, 2024 | Director |
| ACLX | Arcellx, Inc. | Mar 15, 2024 | 5 | -$565K | 4 | Mar 18, 2024 | Director |
| ACLX | Arcellx, Inc. | Jun 14, 2023 | 1 | $0 | 4 | Jun 16, 2023 | Director |
| RVNC | Revance Therapeutics, Inc. | May 3, 2023 | 2 | $0 | 4 | May 5, 2023 | Director |
| ACLX | Arcellx, Inc. | May 16, 2022 | 1 | $0 | 4 | May 17, 2022 | Director |
| ACLX | Arcellx, Inc. | May 16, 2022 | 0 | $0 | 3 | May 17, 2022 | Director |
| RVNC | Revance Therapeutics, Inc. | May 4, 2022 | 1 | $0 | 4/A | May 13, 2022 | Director |
| RVNC | Revance Therapeutics, Inc. | May 5, 2021 | 2 | $0 | 4 | May 7, 2021 | Director |